Video-urodynamic effects of vibegron, a new selective β3-adrenoceptor agonist, on antimuscarinic-resistant neurogenic bladder dysfunction in patients with spina bifida.
neurogenic bladder dysfunction
spina bifida
urodynamics
vibegron
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
01
07
2021
accepted:
16
09
2021
pubmed:
6
10
2021
medline:
20
1
2022
entrez:
5
10
2021
Statut:
ppublish
Résumé
To evaluate the efficacy, safety and tolerability of vibegron for the treatment of antimuscarinic-resistant neurogenic bladder dysfunction in patients with spina bifida. In this retrospective study, 15 patients with antimuscarinic-resistant neurogenic bladder dysfunction due to spina bifida underwent a video-urodynamic study before and during the administration of vibegron 50 mg once daily instead of antimuscarinic agents from February 2019 through April 2021. The video-urodynamic study was carried out to evaluate bladder compliance, maximum cystometric bladder capacity, detrusor overactivity, detrusor leak point pressure and vesicoureteral reflux before and >3 months after the beginning of vibegron administration. Treatment with vibegron significantly improved bladder compliance and maximum cystometric bladder capacity compared with antimuscarinic agents, respectively (7.4 ± 4.2 vs 30.4 ± 48.2 mL/cmH Favorable efficacy of vibegron for antimuscarinic-resistant neurogenic bladder dysfunction due to spina bifida was shown video-urodynamically without apparent adverse events. Vibegron is a favorable option for the treatment of antimuscarinic-resistant neurogenic bladder dysfunction in patients with spina bifida.
Substances chimiques
Muscarinic Antagonists
0
N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide
0
Pyrimidinones
0
Pyrrolidines
0
Receptors, Adrenergic
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
76-81Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 The Japanese Urological Association.
Références
Oefelein MG. Safety and tolerability profiles of antichorinergic agents used for the treatment of overactive bladder. Drug. Saf. 2011; 34: 733-54.
Veenboer PW, Bosch JLHR. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J. Urol. 2014; 191: 1003-8.
Chapple CR, Nazir J, Hakimi Z et al. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur. Urol. 2017; 72: 389-99.
Kamei J, Furuta A, Akiyama Y et al. Video-urodynamic effects of mirabegron, a β3-adrenoceptor agonist, in patients with low-compliance bladder. Int. J. Urol. 2015; 22: 956-61.
Austin PF, Bauer SB, Bower W et al. The standardization of terminology of lower urinary tract function in children and adolescents: update report from the standardization committee of the International Children’s Continence Society. J. Urol. 2014; 191: 1863-5.
Ogawa T. Bladder deformities in patients with neurogenic bladder dysfunction. Urol. Int. 1991; 47: 59-62.
Lebowitz RL, Olbing H, Parkkulainen KV, Smellie JM, Tamminen-Möbius TE. International system of radiographic grading of vesicoureteric reflux. International Reflux Study in Children. Pediatr. Radiol. 1985; 15: 105-9.
Bauer SB. The management of the myelodysplastic child: a paradigm shift. BJU. Int. 2003; 92: 23-8.
Brock JW III, Thomas JC, Baskin LS et al. Effect of prenatal repair of myelomeningocele on urological outcomes at school age. J. Urol. 2019; 202: 812-8.
Houtrow AJ, Thom EA, Fletcher JM et al. Prenatal repair of myelomeningocele and school-age functional outcomes. Pediatrics 2020; 145: e20191544.
Dik P, Klijn AJ, van Gool JD, de Jong-de Vos CC, de Jong TP. Early start to therapy preserves kidney function in spina bifida patients. Eur. Urol. 2006; 49: 908-13.
Ozel SK, Dokumcu Z, Akyildiz C, Avanoglu A, Ulman I. Factors affecting renal scar development in children with spina bifida. Urol. Int. 2007; 79: 133-6.
Kasabian NG, Bauer SB, Dyro FM, Colodny AH, Mandell J, Retik AB. The prophylactic value of clean intermittent catheterization and anticholinergic medication in newborns and infants with myelodysplasia at risk of developing urinary tract deterioration. Am. J. Dis. Child 1992; 146: 840-3.
Kaefer M, Pabby A, Kelly M, Darbey M, Bauer SB. Improved bladder function after prophylactic treatment of the high risk neurogenic bladder in newborns with myelomeningocele. J. Urol. 1999; 162: 1068-71.
Kari JA, Safdar O, Jamjoom R, Anshasi W. Renal involvement in children with spina bifida. Saudi J. Kidney Dis. Transpl. 2009; 20: 102-5.
Kochakarn W, Ratana-Olarn K, Lertsithichai P, Roongreungsilp U. Follow-up of long-term treatment with clean intermittent catheterization for neurogenic bladder in children. Asian J. Surg. 2004; 27: 134-6.
Park JM, Bauer SB, Freeman MR, Peters CA. Oxybutynin chloride inhibits proliferation and suppresses gene expression in bladder smooth muscles cells. J. Urol. 1999; 162: 1110-4.
Dehvari N, da Silver Junior ED, Bengtsson T, Hutchinson DS. Mirabegron: potential off target effects and uses beyond the bladder. Br. J. Pharmacol. 2018; 175: 4072-82.
Edmondson SD, Zhu C, Kar NF et al. Discover of vibegron: a potent and selective beta3 adrenergic receptor agonist for the treatment of overactive bladder. J. Med. Chem. 2016; 59: 609-23.
Yoshida M, Kakizaki H, Takahashi S, Nagai S, Kurose T. Long-term safety and efficacy of the novel β3-adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: a phase III prospective study. Int. J. Urol. 2018; 25: 668-75.
Mitcheson HD, Samanta S, Muldowney K et al. Vibegron (RVT-901/MK-4618/KRP-114V) administrated once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIIb, randomized, double-blind, controlled trial. Eur. Urol. 2019; 75: 274-82.
Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. Once-daily vibegron 75 mg for overactive bladder: long-term safety and efficacy from a double-blind extension study of the international phase 3 trial (EMPOWUR). J. Urol. 2021; 205: 1421-9.
Fujinaga S, Watanabe Y, Nakagawa M. Efficacy of the novel selective β3-adrenoreceptor agonist vibegron for treatment-resistant monosymptomatic nocturnal enuresis in children. Int. J. Urol. 2020; 27: 693-4.
Kato K, Mizuno K, Nishio H, Yasui T, Hayashi Y. Urodynamic effectiveness of a beta-3 adrenoreceptor agonist (vibegron) for a pediatric patient with anticholinergic-resistant neurogenic detrusor overactivity: a case report. J. Med. Case Rep. 2021; 15: 86.
Igawa Y, Aizawa N, Michel MC. β3-adrenoceptors in the normal and diseased urinary bladder - what are the open questions? Br. J. Pharmacol. 2019; 176: 2525-38.
Gotoh D, Shimizu N, Wada N et al. Effects of a new β3-adrenoceptor agonist, vibegron, on neurogenic bladder dysfunction and remodeling in mice with spinal cord injury. Neurourol. Urodyn. 2020; 39: 2120-7.
Nantel F, Bouvier M, Strosberg AD, Marullo S. Functional effects of long-term activation on human β2- and β3-adrenoceptor signalling. Br. J. Pharmacol. 1995; 114: 1045-51.